Achillion Pharma (ACHN) reported earnings on Tue 8 Aug 2017 (a/h)

** charts before earnings **

 

** charts after earnings **

 

Achillion Pharma reports EPS in-line

• Reports Q2 (Jun) loss of $0.16 per share, in-line with the Capital IQ Consensus of ($0.16).
• Updates:
  • Phase 2 clinical trials for untreated paroxysmal nocturnal hemoglobinuria (PNH)
    • To date, Achillion has data for four patients with PNH, two of whom have completed the three-month trial and have entered the long-term extension trial. One additional patient continues to receive dosing in the three-month trial and a fourth patient voluntarily withdrew from the trial on day 41 for reasons unrelated to safety. In summary, interim data from these ongoing trials demonstrated that ACH-4471 achieved clinically meaningful complement inhibition and demonstrated a favorable tolerability profile with no reports of clinically meaningful increases in liver enzymes. In this emerging data set, ACH-4471 has improved LDH, hemoglobin, fatigue score and other measures of response including PNH clone size. These interim results support the Company's global expansion plans for the PNH clinical program.
  • C3 glomerulopathy (C3G)
    
    • During the second half of 2017, Achillion anticipates initiating patient dosing in a phase 2 open-label trial of ACH-4471 for patients with low C3 levels due to C3G or immune-complex membranoproliferative glomerulonephritis (IC-MPGN). This 14-day trial is expected to enroll approximately 10 patients.
  • Update on World-wide Collaboration with Janssen (JNJ) for Chronic Hepatitis C Viral Infection (HCV)
    • In April 2017, Achillion reported that Janssen's OMEGA-1 global phase 2b clinical trial was fully enrolled with a total of 365 subjects. Results from this trial are anticipated during the second half of 2017.
• Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2017 were $369.9 million.